{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:29:26Z","timestamp":1794508166802,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Center,United States","award":["RO1 CA210637"],"award-info":[{"award-number":["RO1 CA210637"]}]},{"name":"National Cancer Center,United States","award":["R01 CA247471"],"award-info":[{"award-number":["R01 CA247471"]}]},{"name":"National Cancer Center,United States,","award":["R44 CA235991"],"award-info":[{"award-number":["R44 CA235991"]}]},{"name":"National Cancer Center,United States,","award":["R44 CA235991"],"award-info":[{"award-number":["R44 CA235991"]}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["PO1 CA217798"],"award-info":[{"award-number":["PO1 CA217798"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01046-w","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T04:46:08Z","timestamp":1755837968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting cancer-associated fibroblast-driven LIF\/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Rakesh","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathy","family":"Seshacharyulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa Wajih","family":"Alsafwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Bhyravbhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moorthy P.","family":"Ponnusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokenge","family":"Malafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhamma","family":"Bindu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gulzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareesh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"1046_CR1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M. & Maitra, A. Pancreatic cancer: Advances and challenges. Cell 186, 1729\u20131754 (2023).","journal-title":"Cell"},{"key":"1046_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","volume":"5","author":"A Bulle","year":"2020","unstructured":"Bulle, A. & Lim, K.-H. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct. Target. Ther. 5, 249 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1046_CR3","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"1046_CR4","first-page":"550","volume":"61","author":"M Lohr","year":"2001","unstructured":"Lohr, M. et al. Transforming growth factor-\u03b21 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550\u2013555 (2001).","journal-title":"Cancer Res."},{"key":"1046_CR5","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.1158\/0008-5472.CAN-10-0785","volume":"70","author":"E Giannoni","year":"2010","unstructured":"Giannoni, E. et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 70, 6945\u20136956 (2010).","journal-title":"Cancer Res."},{"key":"1046_CR6","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1158\/1078-0432.CCR-08-0291","volume":"14","author":"JM Bailey","year":"2008","unstructured":"Bailey, J. M. et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 14, 5995\u20136004 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1046_CR7","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1371\/journal.pmed.0050019","volume":"5","author":"K Pietras","year":"2008","unstructured":"Pietras, K., Pahler, J., Bergers, G. & Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008).","journal-title":"PLoS Med."},{"key":"1046_CR8","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1038\/sj.onc.1203785","volume":"19","author":"Z-M Shao","year":"2000","unstructured":"Shao, Z.-M., Nguyen, M. & Barsky, S. H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19, 4337\u20134345 (2000).","journal-title":"Oncogene"},{"key":"1046_CR9","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2353\/ajpath.2010.090899","volume":"177","author":"Z Xu","year":"2010","unstructured":"Xu, Z. et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177, 2585\u20132596 (2010).","journal-title":"Am. J. Pathol."},{"key":"1046_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05351-1","volume":"13","author":"T Zhang","year":"2022","unstructured":"Zhang, T., Ren, Y., Yang, P., Wang, J. & Zhou, H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).","journal-title":"Cell Death Dis."},{"key":"1046_CR11","doi-asserted-by":"crossref","unstructured":"Sperb, N., Tsesmelis, M. & Wirth, T. Crosstalk between tumor and stromal cells in pancreatic ductal Adenocarcinoma. Int. J. Mol. Sci. 21 (2020).","DOI":"10.3390\/ijms21155486"},{"key":"1046_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MPA.0000000000001249","volume":"48","author":"A Begum","year":"2019","unstructured":"Begum, A. et al. Direct interactions with cancer-associated fibroblasts lead to enhanced pancreatic cancer stem cell function. Pancreas 48, 329\u2013334 (2019).","journal-title":"Pancreas"},{"key":"1046_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41586-019-1130-6","volume":"569","author":"Y Shi","year":"2019","unstructured":"Shi, Y. et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature 569, 131\u2013135 (2019).","journal-title":"Nature"},{"key":"1046_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11044-9","volume":"10","author":"M-T Wang","year":"2019","unstructured":"Wang, M.-T. et al. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat. Commun. 10, 3055 (2019).","journal-title":"Nat. Commun."},{"key":"1046_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med."},{"key":"1046_CR16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1158\/1535-7163.MCT-19-0605","volume":"18","author":"Y Shi","year":"2019","unstructured":"Shi, Y., Hunter, S. & Hunter, T. Stem cell factor lifted as a promising clinical target for cancer therapy. Mol. Cancer Ther. 18, 1337\u20131340 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"1046_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible?. Nat. Rev. Drug Discov. 13, 828\u2013851 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1046_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/MCB.23.2.543-554.2003","volume":"23","author":"J-I Park","year":"2003","unstructured":"Park, J.-I., Strock, C. J., Ball, D. W. & Nelkin, B. D. The Ras\/Raf\/MEK\/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor\/JAK\/STAT pathway. Mol. Cell. Biol. 23, 543\u2013554 (2003).","journal-title":"Mol. Cell. Biol."},{"key":"1046_CR19","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.cell.2013.11.004","volume":"155","author":"JE Toettcher","year":"2013","unstructured":"Toettcher, J. E., Weiner, O. D. & Lim, W. A. Using optogenetics to interrogate the dynamic control of signal transmission by the Ras\/Erk module. Cell 155, 1422\u20131434 (2013).","journal-title":"Cell"},{"key":"1046_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.cytogfr.2015.07.001","volume":"26","author":"NA Nicola","year":"2015","unstructured":"Nicola, N. A. & Babon, J. J. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 26, 533\u2013544 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1046_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s42003-021-01928-2","volume":"4","author":"SA Hunter","year":"2021","unstructured":"Hunter, S. A. et al. An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy. Commun. Biol. 4, 452 (2021).","journal-title":"Commun. Biol."},{"key":"1046_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100530","volume":"7","author":"E Borazanci","year":"2022","unstructured":"Borazanci, E. et al. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open 7, 100530 (2022).","journal-title":"ESMO Open"},{"key":"1046_CR23","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao, L. C., Force, J. & Hartman, Z. C. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 81, 4641\u20134651 (2021).","journal-title":"Cancer Res."},{"key":"1046_CR24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.gendis.2021.04.003","volume":"9","author":"S Viswanadhapalli","year":"2022","unstructured":"Viswanadhapalli, S., Dileep, K. V., Zhang, K. Y. J., Nair, H. B. & Vadlamudi, R. K. Targeting LIF\/LIFR signaling in cancer. Genes Dis. 9, 973\u2013980 (2022).","journal-title":"Genes Dis."},{"key":"1046_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1535-7163.MCT-18-1258","volume":"18","author":"S Viswanadhapalli","year":"2019","unstructured":"Viswanadhapalli, S. et al. EC359: a first-in-class small-molecule inhibitor for targeting oncogenic LIFR signaling in triple-negative breast cancer. Mol. Cancer Ther. 18, 1341\u20131354 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"1046_CR26","doi-asserted-by":"publisher","first-page":"17426","DOI":"10.3390\/ijms242417426","volume":"24","author":"N Spencer","year":"2023","unstructured":"Spencer, N. et al. The LIFR inhibitor EC359 effectively targets Type II endometrial cancer by blocking LIF\/LIFR oncogenic signaling. Int. J. Mol. Sci. 24, 17426 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/13543784.2023.2206558","volume":"32","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Targeting leukemia inhibitory factor in pancreatic adenocarcinoma. Expert Opin. Investig. Drugs 32, 387\u2013399 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1046_CR28","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1016\/S0021-9258(19)50009-6","volume":"267","author":"DJ Hilton","year":"1992","unstructured":"Hilton, D. J. & Nicola, N. A. Kinetic analyses of the binding of leukemia inhibitory factor to receptor on cells and membranes and in detergent solution. J. Biol. Chem. 267, 10238\u201310247 (1992).","journal-title":"J. Biol. Chem."},{"key":"1046_CR29","doi-asserted-by":"publisher","first-page":"693724","DOI":"10.3389\/fonc.2021.693724","volume":"11","author":"J Christianson","year":"2021","unstructured":"Christianson, J., Oxford, J. T. & Jorcyk, C. L. Emerging perspectives on leukemia inhibitory factor and its receptor in cancer. Front. Oncol. 11, 693724 (2021).","journal-title":"Front. Oncol."},{"key":"1046_CR30","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1053\/j.gastro.2021.08.023","volume":"161","author":"P Nallasamy","year":"2021","unstructured":"Nallasamy, P. et al. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1\u2013CD44 Axis. Gastroenterology 161, 1998\u20132013.e1997 (2021).","journal-title":"Gastroenterology"},{"key":"1046_CR31","first-page":"686","volume":"14","author":"MW Saif","year":"2013","unstructured":"Saif, M. W. US Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane\u00ae) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP 14, 686\u2013688 (2013).","journal-title":"JOP"},{"key":"1046_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. nab-Paclitaxel mechanisms of action and delivery. J. Control. Relase170, 365\u2013372 (2013).","journal-title":"J. Control. Relase"},{"key":"1046_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1046_CR34","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1046_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/0008-5472.CAN-15-2790","volume":"78","author":"C Bressy","year":"2018","unstructured":"Bressy, C. et al. LIF drives neural remodeling in pancreatic cancer and offers a new candidate biomarker. Cancer Res 78, 909\u2013921 (2018).","journal-title":"Cancer Res"},{"key":"1046_CR36","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1158\/1538-7445.AM2024-5998","volume":"84","author":"B Ebrahimi","year":"2024","unstructured":"Ebrahimi, B. et al. Pharmacological inhibition of the LIF-LIFR autocrine loop reveals vulnerability of ovarian cancer to ferroptosis. Cancer Res. 84, 5998\u20135998 (2024).","journal-title":"Cancer Res."},{"key":"1046_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00603-z","volume":"7","author":"W Tang","year":"2021","unstructured":"Tang, W. et al. LIF\/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer. Cell Death Discov. 7, 216 (2021).","journal-title":"Cell Death Discov."},{"key":"1046_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.gendis.2022.10.016","volume":"10","author":"C-Z Feng","year":"2023","unstructured":"Feng, C.-Z. et al. The LIFR-targeting small molecules EC330\/EC359 are potent ferroptosis inducers. Genes Dis. 10, 735 (2023).","journal-title":"Genes Dis."},{"key":"1046_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308637","volume":"11","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Disruption of super-enhancers in activated pancreatic stellate cells facilitates chemotherapy and immunotherapy in pancreatic cancer. Adv. Sci. 11, 2308637 (2024).","journal-title":"Adv. Sci."},{"key":"1046_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487\u2013505 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1046_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-494","volume":"10","author":"SA Greco","year":"2010","unstructured":"Greco, S. A. et al. Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that exhibits age-related methylation. BMC Cancer 10, 494 (2010).","journal-title":"BMC Cancer"},{"key":"1046_CR42","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41428-020-0334-9","volume":"52","author":"SR Nasrin","year":"2020","unstructured":"Nasrin, S. R. et al. Comparison of microtubules stabilized with the anticancer drugs cevipabulin and paclitaxel. Polym. J. 52, 969\u2013976 (2020).","journal-title":"Polym. J."},{"key":"1046_CR43","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.celrep.2014.04.036","volume":"7","author":"J Albrengues","year":"2014","unstructured":"Albrengues, J. et al. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep. 7, 1664\u20131678 (2014).","journal-title":"Cell Rep."},{"key":"1046_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1447-0756.2008.00935.x","volume":"35","author":"LL Chen","year":"2009","unstructured":"Chen, L. L. et al. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J. Obstet. Gynaecol. Res. 35, 212\u2013218 (2009).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"1046_CR45","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","volume":"110","author":"D Duluc","year":"2007","unstructured":"Duluc, D. et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110, 4319\u20134330 (2007).","journal-title":"Blood"},{"key":"1046_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10369-9","volume":"10","author":"M Pascual-Garc\u00eda","year":"2019","unstructured":"Pascual-Garc\u00eda, M. et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. Nat. Commun. 10, 2416 (2019).","journal-title":"Nat. Commun."},{"key":"1046_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/1078-0432.CCR-21-1888","volume":"29","author":"RM Hallett","year":"2023","unstructured":"Hallett, R. M. et al. Therapeutic targeting of LIF overcomes macrophage-mediated immunosuppression of the local tumor microenvironment. Clin. Cancer Res. 29, 791\u2013804 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1046_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2174\/1871520620666200717143109","volume":"21","author":"I Khan","year":"2021","unstructured":"Khan, I., Mahfooz, S., Saeed, M., Ahmad, I. & Ansari, I. A. Andrographolide inhibits proliferation of colon cancer SW-480 cells via downregulating notch signaling pathway. Anticancer Agents Med Chem. 21, 487\u2013497 (2021).","journal-title":"Anticancer Agents Med Chem."},{"key":"1046_CR49","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1080\/01635581.2020.1828942","volume":"73","author":"I Khan","year":"2021","unstructured":"Khan, I., Mahfooz, S., Faisal, M., Alatar, A. A. & Ansari, I. A. Andrographolide induces apoptosis and cell cycle arrest through inhibition of aberrant hedgehog signaling pathway in colon cancer cells. Nutr. Cancer 73, 2428\u20132446 (2021).","journal-title":"Nutr. Cancer"},{"key":"1046_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00423-7","volume":"7","author":"A Shah","year":"2023","unstructured":"Shah, A. et al. Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. npj Precis. Oncol. 7, 74 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1046_CR51","doi-asserted-by":"publisher","first-page":"112043","DOI":"10.1016\/j.celrep.2023.112043","volume":"42","author":"S Rauth","year":"2023","unstructured":"Rauth, S. et al. Elevated PAF1-RAD52 axis confers chemoresistance to human cancers. Cell Rep. 42, 112043 (2023).","journal-title":"Cell Rep."},{"key":"1046_CR52","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41388-022-02587-1","volume":"42","author":"R Bhatia","year":"2023","unstructured":"Bhatia, R. et al. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Oncogene 42, 759\u2013770 (2023).","journal-title":"Oncogene"},{"key":"1046_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1104-x","volume":"9","author":"L Wei","year":"2018","unstructured":"Wei, L. et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1\/SATB-1 pathway in pancreatic cancer. Cell Death Dis. 9, 1065 (2018).","journal-title":"Cell Death Dis."},{"key":"1046_CR54","first-page":"3055","volume":"17","author":"FT Wang","year":"2019","unstructured":"Wang, F. T., Sun, W., Zhang, J. T. & Fan, Y. Z. Cancer\u2011associated fibroblast regulation of tumor neo\u2011angiogenesis as a therapeutic target in cancer. Oncol. Lett. 17, 3055\u20133065 (2019).","journal-title":"Oncol. Lett."},{"key":"1046_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-20-1293","volume":"81","author":"K Ganguly","year":"2021","unstructured":"Ganguly, K. et al. Secretory mucin 5AC promotes neoplastic progression by augmenting KLF4-mediated pancreatic cancer cell stemness. Cancer Res. 81, 91\u2013102 (2021).","journal-title":"Cancer Res."},{"key":"1046_CR56","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1038\/onc.2014.409","volume":"34","author":"S Kumar","year":"2015","unstructured":"Kumar, S. et al. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene 34, 4879\u20134889 (2015).","journal-title":"Oncogene"},{"key":"1046_CR57","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/1541-7786.MCR-21-0888","volume":"20","author":"S Marimuthu","year":"2022","unstructured":"Marimuthu, S. et al. MUC16 promotes liver metastasis of pancreatic ductal Adenocarcinoma by upregulating NRP2-associated cell adhesion. Mol. Cancer Res. 20, 1208\u20131221 (2022).","journal-title":"Mol. Cancer Res."},{"key":"1046_CR58","doi-asserted-by":"publisher","first-page":"215922","DOI":"10.1016\/j.canlet.2022.215922","volume":"551","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Small molecule inhibitor against onco-mucins disrupts Src\/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Cancer Lett. 551, 215922 (2022).","journal-title":"Cancer Lett."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01046-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01046-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01046-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:53:31Z","timestamp":1757415211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01046-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01046-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.B. is one of the founders of Sanguine Diagnostics and Therapeutics, Inc. H.N., S.B. and A.G. are employees of Evestra and holders of a patent on EC359. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}